Enzyme replacement therapy for fabry disease: A systematic review of available evidence

Drugs

Volumn 69, Issue 16, 2009, Pages 2179-2205

  Schaefer, Roland M ^a   Tylki Szymańska, Anna ^b   Hilz, Max J ^c,d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; GLOBOTRIAOSYLCERAMIDE;

CLINICAL TRIAL; ENZYME METABOLISM; ENZYME REPLACEMENT; FABRY DISEASE; FEVER; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FUNCTION; NEUROPATHIC PAIN; PROTEINURIA; REVIEW; RIGOR; SWEAT TEST; SYSTEMATIC REVIEW;

ALPHA-GALACTOSIDASE; CHILD; CLINICAL TRIALS AS TOPIC; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE; TRIHEXOSYLCERAMIDES;

EID: 70350509103     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318300-000000000-00000     Document Type: Review

References (65)

1. Wanner C. Fabry disease model: a rational approach to the management of Fabry disease [published erratum appears in Clin Ther 2007 Oct; 29 (10): 2268]. Clin Ther 2007; 29 Suppl. A: S2-5
2. Deegan PB, Baehner AF, Barba Romero MA, et al., European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43 (4): 347-352
3. Wang RY, Lelis A, Mirocha J, et al. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007 Jan; 9 (1): 34-45
4. Wilcox WR, Oliveira JP, Hopkin RJ, et al., Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008 Feb; 93 (2): 112-128
5. Ortiz A, Oliveira JP, Waldek S, et al., Fabry Registry. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008 May; 23 (5): 1600-1607
6. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004 Mar; 34 (3): 236-242
7. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007 Apr; 30 (2): 184-192
8. Cable WJ, Kolodny EH, Adams RD. Fabry disease: im-paired autonomic function. Neurology 1982 May; 32 (5): 498-502
9. Low M, Nicholls K, Tubridy N, et al. Neurology of Fabry disease. Intern Med J 2007 Jul; 37 (7): 436-447
10. Møller AT, Jensen TS. Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol 2007 Feb; 3 (2): 95-106
11. Ries M, Ramaswami U, Parini R, et al. The early clinical phenotype of Fabry disease: a study on 35 European chil-dren and adolescents. Eur J Pediatr 2003 Nov; 162 (11): 767-772
12. Ramaswami U, Whybra C, Parini R, et al., FOS European Investigators. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Pae-diatr 2006 Jan; 95 (1): 86-92
13. Gubler MC, Lenoir G, Grunfeld JP, et al. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 1978 Mar; 13 (3): 223-235
14. Sessa A, Meroni M, Battini G, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001; 24 Suppl. 2: 66-70
15. Grunfeld JP, Lidove O, Joly D, et al. Renal disease in Fabry patients. J Inherit Metab Dis 2001; 24 Suppl. 2: 71-74
16. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002 Jun; 13 Suppl. 2: S139-43
17. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002 Jan; 61 (1): 249-255 (Pubitemid 34075152)
18. Kampmann C, Baehner F, Whybra C, et al. Cardiac manifes-tations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002 Nov; 40 (9): 1668-1674
19. LinhartA,Kampmann C,Zamorano JL,etal., European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007 May; 28, 10, 1228-1235.
20. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996 Jul; 40 (1): 8-17
21. Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 2006 Sep; 5 (9): 791-795
22. Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002 Jun; 11 (4): 317-327
23. Cole AL, Lee PJ, Hughes DA, et al. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 2007 Nov; 30 (6): 943-951
24. Vedder AC, Strijland A, vd Bergh Weerman MA, et al. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 2006 Feb; 29 (1): 106-111
25. Aerts JM, Groener JE, Kuiper S, et al. Elevated globo-triaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008 Feb; 105 (8): 2812-2817
26. Blom D, Speijer D, Linthorst GE, et al. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet 2003 Jan; 72 (1): 23-31
27. Lee K, Jin X, Zhang K, et al. A biochemical and pharma-cological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiol-ogy 2003 Apr; 13 (4): 305-313
28. Sakuraba H, Murata-Ohsawa M, Kawashima I, et al. Com-parison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2006; 51 (3): 180-188
29. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008 Jul; 94 (3): 319-325
30. Eng CM, Guffon N, Wilcox WR, et al., International Col-laborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001 Jul; 345 (1): 9-16
31. Thurberg BL, Byers HR, Granter SR, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004 Apr; 122 (4): 900-908
32. Bierer G, Balfe D, Wilcox WR, et al. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2006 Aug; 29 (4): 572-579
33. Banikazemi M, Bultas J, Waldek S, et al., Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007 Jan; 146 (2): 77-86
34. Schiffmann R, Kopp JB, Austin 3rd HA, et al. Enzyme re-placement therapy in Fabry disease: a randomized controlled trial. JAMA 2001 Jun; 285 (21): 2743-2749
35. Moore DF, Altarescu G, Herscovitch P, et al. Enzyme re-placement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002 Jun; 2: 4
36. Hajioff D, Goodwin S, Quiney R, et al. Hearing improve-ment in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 2003 Dec; 92 (443): 28-30 (Pubitemid 38134746)
37. Schiffmann R, Hauer P, Freeman B, et al. Enzyme replace-ment therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006 Jul; 34 (1): 53-56
38. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replace-ment therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008 Feb; 94 (2): 153-158
39. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clin-ical trial of enzyme replacement in Fabry disease: pharma-cokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001 Mar; 68 (3): 711-722
40. Thurberg BL, Rennke H, Colvin RB, et al. Globo-triaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002 Dec; 62 (6): 1933-1946
41. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardio-myopathy: evidence for a better outcome with early treatment. Circulation 2009 Feb; 119 (4): 524-529
42. Hilz MJ, Brys M, Marthol H, et al. Enzyme replacement therapy improves function of C-, Aq-, and Ab-nerve fibers in Fabry neuropathy. Neurology 2004 Apr; 62 (7): 1066-1072
43. Wilcox WR, Banikazemi M, Guffon N, et al., International Fabry Disease Study Group. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004 Jul; 75 (1): 65-74
44. Eto Y, Ohashi T, Utsunomiya Y, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 2005; 28 (4): 575-583
45. Pisani A, Spinelli L, Sabbatini M, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005 Jul; 46 (1): 120-127
46. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006 May; 97 (10): 1515-1518
47. Breunig F, Weidemann F, Strotmann J, et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006 Apr; 69 (7): 1216-1221
48. Kalliokoski RJ, Kantola I, Kalliokoski KK, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 2006 Feb; 29 (1): 112-118
49. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007 May; 18 (5): 1547-1557
50. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003 Dec; 28 (6): 703-710
51. Schiffmann R, Ries M, Timmons M, et al. Long-term ther-apy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006 Feb; 21 (2): 345-354
52. Clarke JT, West ML, Bultas J, et al. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 2007 Aug; 9 (8): 504-509
53. Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007 May; 18 (5): 1576-1583
54. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsi-dase alfa or beta at a dose of 0.2 mg/kg. PloS ONE 2007 Jul; 2 (7): e598
55. Baehner F, Kampmann C, Whybra C, et al. Enzyme re-placement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003; 26 (7): 617-627
56. Wraith JE, Tylki-Szymanska A, Guffon N, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008 Apr; 152 (4): 563-570
57. Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006 Sep; 118 (3): 924-932
58. Ramaswami U, Wendt S, Pintos-Moreli G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007 Jan; 96 (1): 122-127
59. Ries M, Clarke JT, Whybra C, et al. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J Clin Pharmacol 2007 Oct; 47 (10): 1222-1230
60. Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylcer-amide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000 Jan; 97 (1): 365-370
61. Ohashi T, Sakuma M, Kitagawa T, et al. Influence of anti-body formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 2007 Nov; 92 (3): 271-273
62. Linthorst GE, Hollak CE, Donker-Koopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004 Oct; 66 (4): 1589-1595
63. Mengel E, Baron K, Kalkum G, et al. Is there a neutralizing effect of antibodies against agalsidase alpha and agalsidase beta? Acta Paediatr 2007; 96 (s455): 108
64. Vedder AC, Cox-Brinkman J, Hollak CE, et al. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 2006 Nov; 89 (3): 239-44
65. Mignani R, Feriozzi S, Pisani A, et al. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 2008 May; 23 (5): 1628-35